BUDGETARY IMPACT OF ALIROCUMAB REPACKAGING IN A THIRD LEVEL HOSPITAL

Authors: N. BÁEZ, C. ROMERO LARA, MD. SANTOS RUBIO, M. MUÑOZ BURGOS, H. RODRÍGUEZ RAMALLO.
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO, HOSPITAL PHARMACY, SEVILLE, SPAIN.

Background
Although parenteral nutrition (PN) is a lifesaving therapy in undernourished patients, its use may be associated with metabolic complications.

Purpose
To evaluate the budgetary impact of the repackaging of the commercial dose of 150 mg in doses of 75 mg.

Materials
A pharmacoeconomic study was carried out in which the savings obtained by repacking the dose of 150 mg in doses of 75 mg both commercial presentations have the same price.

The cost was calculated, taking into account the number of doses and the duration of treatment in each patient.

Results:
- 73 patients were treated with alirocumab during the period of study.
- A saving of € 1077.93 per patient was obtained with the repackaging of the 150 mg dose into 75 mg.

Conclusions
The budgetary impact of the repackaging of the commercial presentation of 150 mg in doses of 75 mg is a cost-effective practice, simple and easy to implement in hospitals.